Tempest Therapeutics Welcomes New VP of Quality Assurance
Tempest Therapeutics, Inc. (Nasdaq: TPST), a biotechnology company in the clinical stage focused on developing innovative targeted and immune-mediated therapies for cancer treatment, has announced the appointment of Troy M. Wagner as the new Vice President of Quality Assurance.
Experience and Contributions
“Troy brings extensive experience in late-stage product development, particularly in managing quality systems across various global clinical trials and aiding in global regulatory submissions. We are excited about her contributions as we progress towards Phase 3 development of amezalpat for hepatocellular carcinoma, and we are delighted to have her join the Tempest leadership team,” stated Stephen Brady, president and CEO of Tempest.
Statement from Troy M. Wagner
Ms. Wagner expressed, “Joining Tempest at this moment is an incredible opportunity. The company’s leading oncology candidate, amezalpat, has produced promising clinical outcomes in liver cancer, showcasing its potential to revolutionize treatment for this historically challenging disease. I am eager to collaborate with the team to bring this promising therapy to patients.”
Troy M. Wagner's Professional Background
Ms. Wagner comes to Tempest with over 30 years of expertise in quality and clinical compliance, having taken on the role of Vice President of Quality Assurance. Her background includes managing compliance, quality assurance, and quality control across various pharmaceutical and device manufacturing sites. She has also provided support as a liaison to regulatory agencies and has overseen the implementation of corporate quality standards.
Before joining Tempest, she served as the Vice President of Quality Assurance at Tricida, Inc., where she was responsible for all quality assurance functions related to manufacturing, testing, holding, and distribution. Prior to her time at Tricida, Ms. Wagner held the position of Head of Global Corporate Quality & Compliance at Jubilant Life Sciences Ltd., and has worked in significant roles at several other companies, including Alcon and Nektar Therapeutics.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology firm that is advancing a diverse range of small molecule product candidates with tumor-targeted and/or immune-mediated mechanisms. These candidates hold promise for treating a variety of tumors. The company’s innovative programs encompass early research through to later-stage investigations in randomized global studies aimed at first-line cancer patients.
Investor Contacts
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Frequently Asked Questions
Who is the new Vice President of Quality Assurance at Tempest?
Troy M. Wagner has been appointed as the new Vice President of Quality Assurance at Tempest Therapeutics.
What experience does Troy M. Wagner bring to Tempest?
Troy M. Wagner brings over 30 years of experience in quality and clinical compliance from various roles in the pharmaceutical industry.
What is the focus of Tempest Therapeutics?
Tempest Therapeutics focuses on developing targeted and immune-mediated therapeutics to fight cancer, with a diverse portfolio of product candidates.
What is the significance of amezalpat for Tempest?
Amezalpat is Tempest's lead oncology candidate, which has shown promising clinical results for treating liver cancer.
How can investors contact Tempest Therapeutics?
Investors can contact Sylvia Wheeler or Aljanae Reynolds at Wheelhouse Life Science Advisors via the provided email addresses.
